The rising price of vitamin amino acids continues to affect a large number of pharmacies

Vitamins, amino acids and other raw materials prices continue to rise, many vitamin varieties of production enterprises helpless, and the most affected is the pharmacy.
With the frequent exposure of many API manufacturers to shut down and rectify the information, market tension is being more and more intense, many middlemen intend to hype some commodities, to vitamin category examples, many people market hoarding intention is obvious. Even some parts of the API manufacturers to take the closure of the temporary offer measures, vitamin varieties will usher in a new round of price increases, a pharmacy head told us.
the price of vitamins increase?
understand that from the second half of 2017, vitamin prices began to rise. Vitamin A from 145 yuan / kg to 850 yuan / kg, vitamin E from 37 yuan / kg to 140 yuan / kg, vitamin C from 32 yuan / kg to 60 yuan / kg, biotin from 64 yuan / kg to 220 yuan / kg.
's going to go up in price by more than one vitamin! Each bottle of isoniazid tablets from 4 yuan, the highest rose to 82
yuan; The price of raw materials generally increased, active or forced helpless?
is the initiative of API enterprises or middlemen monopoly, or environmental protection supervision efforts, production costs rise after being forced to helpless?
is also based on vitamin distance, vitamins are a huge family, there are currently dozens of known vitamins, and the very low-replacement, rigid demand for vitamins is also heavy pollution industry, as well as high barriers to entry monopoly industry.
Many individual vitamin varieties are very concentrated, the basic situation is that 3 to 5 enterprises occupy more than 70% of the market share in the global market, so from the production and supply of vitamin industry basically formed an oligopoly competition pattern.
here, there are many readers think, can not be under the control of the state under the API enterprise market, take administrative measures, more API production enterprises?
, in addition to financial and technical strength, API enterprises access threshold is very high!
According to the National Development and Reform Commission price supervision and inspection and anti-monopoly bureau deputy director Li Qing previously revealed to the media, China's finished drugs have 1500 kinds of RAW drugs, of which only one enterprise has obtained approval qualifications to produce, 44 kinds of API only two enterprises can produce, 40 kinds of API only three enterprises can produce.
10% of the API can only be produced by single-digit production enterprises, API production in the hands of a particularly small number of production enterprises. According to the corresponding proportion of API manufacturers sampling results show that a RAW drug corresponding to a maximum of 169 preparation enterprises, it can be seen that its dominance of the preparation market.
market monopoly competition of raw materials production enterprises, the strength of domestic environmental protection supervision is also an important indicator affecting the price of vitamins.
from the second half of 2017, environmental pressure continued to increase, many pharmacies selling OTC varieties prices soared, in addition to price monopoly, but also because of the rising cost of API procurement.
and for API enterprises, environmental pressure heating season wrong peak production also caused a lot of RAW production costs skyrocke, and even environmental protection pressure, many enterprises directly stop production.
and various factors, may cause the middle layer of API hoarding deliberately increased prices.
the Government's focus on whether large fines are effective?
government regulation, the market monopoly of raw materials, price increases, since last year, the NDRC has been increasing penalties.
November 23, 2017, the website of the National Development and Reform Commission (NDRC) officially published the "Guidelines on Price Behavior of Operators of Shortage drugs and API" (hereinafter referred to as the "Guidelines"), which severely cracked down on the price monopoly of operators of shortage drugs and API.
same time, the National Development and Reform Commission (NDRC) has dealt with cases of abuse of market dominance to sell some of its raw materials at unfairly high prices, and issued hundreds of thousands of high fines.
And many people in the industry believe that in front of the interests, many tickets, although the amount of large, the penalty is also very large, but for many malicious competition of API enterprises or middlemen, perhaps just "nine cattle and one hair"! The industry supports normal market competition and environmental protection pressure a certain range of normal price increases, but the hoarding of raw materials and monopoly behavior, will affect a large number of drugstores common drug species, the fate of many low-cost drugs, and the access of ordinary people to medication, is the national economy and people's livelihood issues.Industry view
" the pharmaceutical industry standards should be controlled by quality, rather than administrative systems, management methods to manage, the current monopoly is not conducive to the health of the market, is not conducive to the development of pharmaceutical enterprises. In March this year, the 10th "voice and responsibility" of the pharmaceutical industry, the National People's Congress of the National People's Political Consultative Conference (CPPCC) symposium, Henan Antelope Pharmaceutical Co., Ltd. Chairman Xiong Weizheng said.
and environmental storms, the supply of phased tightening situation of more than one vitamin, the same affect the price of amino acids, mineral trace elements.Amino acids are rising and out of stock
According to market research reports, the global amino acid market in 2014, the total sales of various amino acid products 6.582 million tons, in 2015 this figure increased to 7.19 million tons, in 2016 nearly 8 million tons.
past few years, the world amino acid market has grown at a compound rate of 5.6%, with total sales expected to reach 11.05 million tons by 2022, when total sales will reach a staggering $35.4 billion or more.
this shows that the amino acid market is quite hot, into 2018 amino acid varieties have been active, and the market seems to be very short, varieties circulation is not much, so little information.price of trace elements doubled
data show that iron sulfate from 0.8 yuan / kg to 4.5 yuan / kg, a nearly 5 times increase! Zinc oxide rose from 15 yuan/kg to 35 yuan/kg, zinc glycine rose from 6.8/kg to 18 yuan/kg, choline chloride rose from 4.7 yuan/kg to 12 yuan/kg;
Eon environmental protection high-pressure, oligopoly, there are enterprises directly stop production
On May 28, one of the production bases of Magic Pharmaceuticals (Longli Branch Factory) received the "Longli County Insurance Bureau Administrative Penalty Decision", "Longli County Environmental Protection Bureau ordered to stop production and rectification decision";
On June 6, Ningxia Terry Pharmaceutical Co., Ltd. was ordered to continue to implement the shutdown and rectification;
On June 6, Ningxia Qiyuan Pharmaceutical Co., Ltd. received a notice to stop the trial operation;
June 10, Jiangxi local enterprises to stop production and rectification;
June 11, Jiuzhou Pharmaceutical Co.,
Ltd. issued a supplementary announcement to stop production.... With the intensity of environmental verification and the government's accelerated flight inspection of pharmaceutical companies and the further improvement of GMP requirements, the API industry has entered a shuffle period. Small and medium-sized raw material manufacturers will continue to face pressure from all sides, had to be forced to withdraw, some traditional large enterprises in environmental inspection and infrastructure to increase investment, but the transformation and upgrading is imminent.
so many raw materials supply will not be guaranteed in the short term, the shortage situation is difficult to alleviate, prices will inevitably rise, a large number of drugstore vitamin varieties sales will be greatly affected. (Pharmacy Manager)